A randomized, double-blind, placebo-controlled study of ATI-2042 in patients with paroxysmal atrial fibrillation and pacemakers with atrial fibrillation data logging capabilities.

Trial Profile

A randomized, double-blind, placebo-controlled study of ATI-2042 in patients with paroxysmal atrial fibrillation and pacemakers with atrial fibrillation data logging capabilities.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2012

At a glance

  • Drugs Budiodarone (Primary)
  • Indications Paroxysmal atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms PASCAL
  • Sponsors ARYx Therapeutics
  • Most Recent Events

    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2012 Patient numbers changed from 110 to 72 as reported in the abstract
    • 14 Nov 2009 Results have been published as an abstract in the proceedings of the 82nd Annual Scientific Sessions of the American Heart Association (AHA) 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top